NCT03466268View on ClinicalTrials.gov

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

Gumarontinib Tablets

Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Haihe Biopharma Co., Ltd.

INDUSTRY